Status and phase
Conditions
Treatments
About
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Supplementary exclusion criteria for subjects with hepatic impairment:
Supplementary exclusion criteria for subjects with normal hepatic function:
Primary purpose
Allocation
Interventional model
Masking
24 participants in 4 patient groups
Loading...
Central trial contact
Yu Chen; LiYan Miao
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal